- Home
- HEPS vs DNTH Comparison
HEPS vs DNTH Comparison
Compare HEPS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- DNTH
- Stock Information
- Founded
- HEPS 2000
- DNTH 2015
- Country
- HEPS Turkey
- DNTH United States
- Employees
- HEPS N/A
- DNTH N/A
- Industry
- HEPS Catalog/Specialty Distribution
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- DNTH Health Care
- Exchange
- HEPS Nasdaq
- DNTH Nasdaq
- Market Cap
- HEPS 811.7M
- DNTH 657.0M
- IPO Year
- HEPS 2021
- DNTH N/A
- Fundamental
- Price
- HEPS $2.66
- DNTH $17.39
- Analyst Decision
- HEPS
- DNTH Strong Buy
- Analyst Count
- HEPS 0
- DNTH 8
- Target Price
- HEPS N/A
- DNTH $53.00
- AVG Volume (30 Days)
- HEPS 348.8K
- DNTH 255.5K
- Earning Date
- HEPS 06-12-2025
- DNTH 05-12-2025
- Dividend Yield
- HEPS N/A
- DNTH N/A
- EPS Growth
- HEPS N/A
- DNTH N/A
- EPS
- HEPS N/A
- DNTH N/A
- Revenue
- HEPS $1,471,066,066.00
- DNTH $6,524,000.00
- Revenue This Year
- HEPS $22.80
- DNTH N/A
- Revenue Next Year
- HEPS $25.49
- DNTH N/A
- P/E Ratio
- HEPS N/A
- DNTH N/A
- Revenue Growth
- HEPS 42.87
- DNTH 102.36
- 52 Week Low
- HEPS $1.71
- DNTH $13.37
- 52 Week High
- HEPS $4.05
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- HEPS 45.42
- DNTH 35.86
- Support Level
- HEPS $2.56
- DNTH $17.40
- Resistance Level
- HEPS $2.90
- DNTH $18.45
- Average True Range (ATR)
- HEPS 0.11
- DNTH 1.21
- MACD
- HEPS 0.00
- DNTH -0.22
- Stochastic Oscillator
- HEPS 29.85
- DNTH 10.60
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.